- Home
- KYTX vs BTMD Comparison
KYTX vs BTMD Comparison
Compare KYTX & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- BTMD
- Stock Information
- Founded
- KYTX 2018
- BTMD 2012
- Country
- KYTX United States
- BTMD United States
- Employees
- KYTX N/A
- BTMD N/A
- Industry
- KYTX
- BTMD Medicinal Chemicals and Botanical Products
- Sector
- KYTX
- BTMD Health Care
- Exchange
- KYTX NYSE
- BTMD Nasdaq
- Market Cap
- KYTX 92.1M
- BTMD 104.2M
- IPO Year
- KYTX 2024
- BTMD N/A
- Fundamental
- Price
- KYTX $2.11
- BTMD $4.00
- Analyst Decision
- KYTX Buy
- BTMD Strong Buy
- Analyst Count
- KYTX 5
- BTMD 1
- Target Price
- KYTX $18.80
- BTMD $8.00
- AVG Volume (30 Days)
- KYTX 205.0K
- BTMD 185.1K
- Earning Date
- KYTX 05-16-2025
- BTMD 05-07-2025
- Dividend Yield
- KYTX N/A
- BTMD N/A
- EPS Growth
- KYTX N/A
- BTMD 123.33
- EPS
- KYTX N/A
- BTMD 0.60
- Revenue
- KYTX N/A
- BTMD $199,379,000.00
- Revenue This Year
- KYTX N/A
- BTMD $6.20
- Revenue Next Year
- KYTX N/A
- BTMD $9.24
- P/E Ratio
- KYTX N/A
- BTMD $6.67
- Revenue Growth
- KYTX N/A
- BTMD 6.44
- 52 Week Low
- KYTX $1.78
- BTMD $3.04
- 52 Week High
- KYTX $17.55
- BTMD $8.44
- Technical
- Relative Strength Index (RSI)
- KYTX 48.82
- BTMD 61.89
- Support Level
- KYTX $1.92
- BTMD $3.15
- Resistance Level
- KYTX $2.38
- BTMD $3.52
- Average True Range (ATR)
- KYTX 0.17
- BTMD 0.22
- MACD
- KYTX 0.02
- BTMD 0.07
- Stochastic Oscillator
- KYTX 41.30
- BTMD 85.37
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.